Q2
BNTX — Q2 2026 Financial Report Analysis
BioNTech Q2 2026: revenue fell 60% to €105.6M as COVID-19 vaccine sales dropped 66%, net loss doubled to €820.8M on restructuring charges, and 2026 revenue guidance was cut to €1.6–1.9B; €16.6B in cash funds the cancer pipeline.